Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.
Park JH, Devlin S, Durham BH, Winer ES, Huntington S, von Keudell G, Vemuri S, Shukla M, Falco V, Cuello B, Gore S, Stone R, Abdel-Wahab O, Tallman MS.
Park JH, et al. Among authors: shukla m.
NEJM Evid. 2023 Oct;2(10):EVIDoa2300074. doi: 10.1056/EVIDoa2300074. Epub 2023 Sep 21.
NEJM Evid. 2023.
PMID: 38320179
Free PMC article.